Arcturus Therapeutics Holdings Inc. ARCT
We take great care to ensure that the data presented and summarized in this overview for Arcturus Therapeutics Holdings Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ARCT
View all-
Federated Hermes, Inc. Pittsburgh, PA4.69MShares$34.1 Million0.16% of portfolio
-
Black Rock Inc. New York, NY2.65MShares$19.3 Million0.0% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.1.95MShares$14.2 Million0.02% of portfolio
-
Nikko Asset Management Americas, Inc.1.95MShares$14.2 Million0.39% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.89MShares$13.7 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl1.87MShares$13.6 Million0.24% of portfolio
-
State Street Corp Boston, MA1.05MShares$7.6 Million0.0% of portfolio
-
Balyasny Asset Management LLC Chicago, IL965KShares$7.02 Million0.02% of portfolio
-
Morgan Stanley New York, NY705KShares$5.12 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY668KShares$4.86 Million0.08% of portfolio
Latest Institutional Activity in ARCT
Top Purchases
Top Sells
About ARCT
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
Insider Transactions at ARCT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 15
2025
|
Andy Sassine Chief Financial Officer |
SELL
Open market or private purchase
|
Direct |
1,238
-0.56%
|
$19,808
$16.56 P/Share
|
|
Oct 15
2024
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
12,000
-2.68%
|
$240,000
$20.76 P/Share
|
|
Jun 14
2024
|
Peter C Farrell Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,131
+5.32%
|
-
|
|
Jun 14
2024
|
James F Barlow Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,131
+19.25%
|
-
|
|
Jun 14
2024
|
Magda Marquet Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,131
+50.0%
|
-
|
|
Jun 14
2024
|
John Markels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,131
+50.0%
|
-
|
|
Jun 14
2024
|
Edward W Holmes Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,131
+50.0%
|
-
|
|
Jun 14
2024
|
Jing L. Marantz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,131
+50.0%
|
-
|
|
Jun 12
2024
|
Andy Sassine Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
50,000
-18.48%
|
$1,600,000
$32.03 P/Share
|
|
Jun 05
2024
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
114
-0.03%
|
$5,130
$45.0 P/Share
|
|
Jun 03
2024
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
26,000
-5.49%
|
$1,040,000
$40.01 P/Share
|
|
Mar 25
2024
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
17,435
-3.55%
|
$610,225
$35.02 P/Share
|
|
Mar 19
2024
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
8,565
-1.71%
|
$299,775
$35.01 P/Share
|
|
Nov 01
2023
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
5,000
-0.99%
|
$90,000
$18.72 P/Share
|
|
Oct 02
2023
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
5,000
-0.98%
|
$125,000
$25.61 P/Share
|
|
Sep 01
2023
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
5,000
-0.97%
|
$155,000
$31.45 P/Share
|
|
Aug 15
2023
|
Andy Sassine Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,223
+0.45%
|
$20,791
$17.37 P/Share
|
|
Aug 01
2023
|
Pad Chivukula Chief Scientific Officer & COO |
SELL
Open market or private sale
|
Direct |
5,000
-0.96%
|
$170,000
$34.91 P/Share
|
|
Jul 14
2023
|
Keith C Kummerfeld Officer |
SELL
Open market or private sale
|
Direct |
6,968
-88.0%
|
$243,880
$35.0 P/Share
|
|
Jul 14
2023
|
Keith C Kummerfeld Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,968
+24.67%
|
$62,712
$9.38 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 1.24K shares |
|---|